GenVivo, Inc.

We are delighted to welcome Dr. Noriyuki Kasahara to the GenVivo team as our new Chief Scientific Officer (CSO). His extensive scientific and developmental expertise will be instrumental as we advance our in vivo CAR-T and IL-12 vector programs into the clinic and validate the GEN2 mechanism of action in our Phase 1/2 clinical trial. We look forward to collaborating with him and achieving impactful milestones together. #Collaboration #Innovation #Biotech #CART #IL12 #GenVivo #GVO #immunotherapy #genetherapy To view our press release in more detail please visit: https://lnkd.in/gBqQWTFV

We are proud to be recognized among the leading companies that are tackling this challenging oncology indication. Our platform is well-suited to deliver therapies to the liver, and we are looking forward to the clinical data from our on-going trial with GEN2 (NCT06391918).

GenVivo is honored to have been invited to present at the Sartorius #PIForum2025. Our colleague, Stephen Hsu, had the privilege of presenting our latest insights on “Developing Process Intensification Requirements for the Production of Enveloped Retrovectors in HEK293T Cells.” This invitation highlights the strength of our team’s expertise and the growing impact of our technologies in advancing gene therapy manufacturing. We extend our sincere thanks to Vincent Lam and the Sartorius team for this recognition and the opportunity to contribute to the ongoing conversation around next-generation bioprocessing in gene therapy. #GVO #GenVivo #GeneTherapy #BioProcessing

GenVivo is proud to be attending the BIO International Convention in Boston, June 16-19, where our team will engage with leaders, collaborators, and innovators across the biotech landscape. A key highlight of the event will be a presentation by our Chief Operating Officer, Robert G. Johnson, MD, PhD, on GenVivo’s Next Generation of Cancer Immunotherapy. He will unveil exciting updates on our advancing pipeline, including: -- Our GEN2 clinical program with news about our expansion phase and upcoming combination arms -- Our novel program for the in vivo CAR-T platform -- The therapeutic potential our product encoding for IL-12 capable of localized delivery for immune activation -- Insights into GenVivo’s robust in-house development and manufacturing capabilities and future product candidates We invite all attendees to connect with us at BIO to learn more on how GenVivo is redefining cancer immunotherapy. For collaboration opportunities or to explore how we can work together, please contact Victor Constantinescu or BD@genvivoinc.com #BIO #BIO2025 #CART #IL12 #GenVivo #GVO #immunotherapy #genetherapy

While at #ASCO2025 this week, the GenVivo team has been engaging in everything from thought provoking keynotes to meaningful hallway conversations -- making this event a great opportunity to learn, connect, and get inspired. If you’re here too, we’d love to connect!

We’re excited to be attending ASCO 2025 this year! The GenVivo team is looking forward to connecting with fellow innovators, leaders, and partners in oncology. As we continue our mission to drive impact in this space, we welcome opportunities to collaborate and explore how we can work together on future projects. If you're attending ASCO and would like to learn more about who we are and what we do, please don’t hesitate to reach out—we’d love to meet you!  Alison Hannah Robert G. Johnson, MD, PhD Victor Constantinescu #ASCO2025 #Oncology #LifeSciences #Collaboration #Innovation #Biotech #GVO

We’re excited to share that GenVivo successfully presented our latest pre-clinical research at #ASGCT2025! Our team showcased a poster titled “Safety and Efficacy of Retroviral Vector GEN-1018 and GEN-1013 Toward Clinical Translation for In Vivo Immuno-Gene Therapy and Combined Suicide Gene Therapy.” The presentation highlighted our innovative strategies in targeted drug delivery and demonstrated promising tolerance and efficacy data as we advance toward clinical application. ASGCT2025 provided an incredible platform to connect with fellow researchers, exchange insights, and receive valuable feedback that will help shape the next phase of our development. A heartfelt thank you to the ASGCT organizers for creating such a dynamic environment for scientific collaboration—and to our dedicated team, whose expertise and passion continue to drive our mission forward. We look ahead with enthusiasm and remain committed to translating groundbreaking science into real-world therapeutic impact.

GenVivo had an invaluable experience sharing our latest research at AACR! Our poster, “IL-12 immunotherapy using a novel gene delivery platform for RNA payloads achieves effective anti-tumor responses without systemic toxicity in an aggressive CT26 murine cancer model”, reflects our commitment to advancing cancer therapies and improving patient outcomes. We’re thrilled to contribute to the global conversation and we’re grateful for the opportunity to collaborate with the incredible scientific community that gathered here. Thank you to the conference organizers and our fellow researchers for the inspiring discussions and breakthroughs being shared! For detailed information check out our website for the poster and press release. #AACR2025 https://lnkd.in/ghyX_bHv

GenVivo is thrilled to support the Lazarex Cancer Foundation, a remarkable organization transforming lives by improving access to cancer treatments. With the generous support of our community, the GenVivo team surpassed our fundraising goal and became the # 1 team fundraiser, raising $11,405 for the 5.44k walk—symbolizing the 544-mile average round-trip journey Lazarex patients make for clinical trials. This achievement reflects our unwavering commitment to a healthier, more equitable future. Heartfelt thanks to the organizers, donors, and everyone who made this impactful cause a success! #Lazarex544k

GenVivo Head of BD and Manufacturing Victor Constantinescu is excited to speak at BioProcess International US West 2025. Join his talk March 18th at 11:00am on “In-House Manufacturing vs. CDMO: Navigating the Choice for Vector-Based Therapies”. Later that day he will also be at the 3:00pm Round Up Panel - "Forging Strategic Alliances: Maximizing Value in CDMO Partnerships". Hope to see you there!